2015年 

The company’s product “Ventricular Septal Defect [VSD] occluder” was launched into the market.

2014年 

The company’s product “Cervical Dilator” waslaunched into the market.

The company’s product “Occluder Delivery System” was launched into the market.

The company moved from Tongsha DongchengScience and Technology Park to “Dongguan Kewei Medical Device Institute”.

2012年9月 

Shanghai MicroPort Medical Device (Group) Co.,Ltd. completed the acquisition of Dongguan Kewei, and up to then, Dongguan Kewei has been the wholy-owned subsidiary of MicroPort Group.

The company was rated as “Dongguan’s ThirdBatch of Municipal Enterprise Technical Center”.

The company’s product “Membrane Oxygenation” wasrated as a national key new product.

The construction project of “Dongguan Kewei MedicalDevice Institute” was started by digging for the foundation.

The company won the title of “Dongguan Scienceand Technology Prize Innovative Enterprise”.

The company won the honor of “Excellent Enterprise in the Campaign of “Boosting Transconformation and Constructing NewDongguan”.

Kewei Brand was rated by GuangdongPharmaceutical Profession Association as “Most Influential Brand in GuangdongMedical Device Industry during the THIRTY YEARS of the Reform and Opening-Up”.

The company’s project “Dongguan Kewei MedicalDevice Institute” was approved by Dongguan Government.

Kewei Brand was rated as “Guangdong Renowned Trademark”.

The company was rated as the first-batch of“National High-Tech Enterprises”.

The company was rated by Guangdong ProvincialFood and Drug Administration as the only “3A Enterprise of Medical Device” in Dongguan.

11 of the company’s 15 products were rated as“Guangdong Provincial High-Tech Products”.

The company was rated as “Guangdong ProvincialPatent Training Enterprise”.

The company moved from Shijing Guanli Area toTongsha Dongcheng Science and Technology Park.

 “Kewei -Membrane Oxygenation” is included into the national torch plan project.

The company was rated as “Guangdong ProvincialPrivate-Owned Science and Technology Enterprise” .

The company’s product “Atrial Septal Defect[ASD] Occluder” was launched into the market.

The company’s product “Patent Ductus Arteriosus[PDA] Occluder” was launched into the market.

The company’s product “Hollow Fiber Hemofilter” waslaunched into the market.

The company’s product “Venous Return   Cannula” was launched into the market.

The company’s product “Generation Membrane Oxygenation System” was launched into the market.

The company’s product “Blood Rservoir” was launched into the market.

The company’s product “Extracorporeal Circulation Tubing” waslaunched into the market.

The company’s product “Arterial Filter” waslaunched into the market.

The company’s product “Cardioplegia Delivery System” waslaunched into the market.

The company’s product “Arterial Cannula” waslaunched into the market.

The company completed the reform ofstock-holding system, and transformed from a military industry enterprise tothe current status.

The company’s product “Bubble Oxygenator” waslaunched into the market.

The company was jointly established by Dongguan Medicine General Company and the Fourth Military Medical University of Chinese People’s Liberation Army.